Although the toxic effects of citrate including hemodynamic and cardiovascular changes result from a decrease in ionized calcium levels in serum due to chelating action, these effects of citrate on blood coagulation have not yet been fully clarified. The present study examines whether serum citrate and ionized calcium levels affect whole blood clotting time in rats using the test tube method in...

objective(s): haemostasis prevents blood loss following vascular injury. it depends on the unique concert of events involving platelets and specific blood proteins, known as coagulation factors. the clotting system requires precise regulation and coordinated reactions to maintain the integrity of the vasculature. clotting insufficiency mostly occurs due to genetically inherited coagulation fact...

Abstract Precise control of blood clotting and rapid reversal anticoagulation are essential in many clinical situations. We were successful modifying a thrombin‐binding aptamer with red‐light photocleavable linker derived from Cy7 by Cu‐catalyzed Click chemistry. able to show that we can successfully deactivate the modified red light (660 nm) even human blood—restoring blood's natural coagulati...

P52 Coagulation is a complex process that results in blood forming clots at tissue and vessel sites where damage has occurred, thereby stopping bleeding. Cardiac surgery extensively alters the normal coagulation process both intentionally and unintentionally. More often than not, cardiac surgery uses cardiopulmonary bypass (CPB) for intervention and surgical correction. Before initiating cardio...

Experimental hypercalcaemia was induced in rats by (1) transplantation of the solid Walker 256 tumour, and (2) intraperitoneal injections of calcium gluconate. Whole blood clotting was studied by means of thromboelastography and whole blood clotting times in polystyrene and glass test tubes. At serum calcium levels between 10.3 and 11.5 m-equiv/l a slight delay in clot formation was found which...

Polyhemoglobin (polyHb) is currently being assessed in phase III trials under various formulations. At present, none contain clotting factors or platelet substitutes to aid in hemostasis. We have prepared a novel blood substitute that is an oxygen carrier with platelet-like activity. This is formed by crosslinking fibrinogen to hemoglobin to form polyhemoglobin-fibrinogen (polyHb-Fg). This was ...